Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China.
Department of Physiology, Xiangya school of Medicine, Central South University, Changsha, Hunan, PR China.
Life Sci. 2019 Apr 15;223:29-37. doi: 10.1016/j.lfs.2019.03.020. Epub 2019 Mar 10.
Renal fibrosis is the most common final stage of progressive renal disease, characterized by fibroblast proliferation, fibroblast-to-myofibroblast differentiation and excessive accumulation of extracellular matrix. Dihydroartemisinin (DHA) exerts antitumor, antibacterial, and antifibrotic effects. The aim of this study was to determine whether DHA has beneficial effects on unilateral ureteral obstruction (UUO)-induced renal fibrosis in mice and to examine explore the underlying possible mechanisms.
Eight-week-old male C57BL/6 mice were intragastrically administered DHA for 14 consecutive days after UUO operation. Afterward, interstitial collagen deposition, expression of collagen I and III, fibronectin, α-smooth muscle actin (α-SMA), proliferating cell nuclear antigen (PCNA), and S100 calcium-binding protein A4 (S100A4) were assessed in the kidneys. Transforming growth factor beta 1 (TGF-β1)-induced primary human kidney fibroblasts were treated with DHA to further investigate the mechanism underlying its action.
In vivo, DHA reduced UUO-induced morphological and pathological changes and the degree of renal fibrosis. In addition, DHA mitigated fibroblast proliferation and differentiation in kidney tissue induced by UUO. In vitro, DHA significantly attenuated the TGF-β1-induced primary human kidney fibroblast proliferation and fibroblast-to-myofibroblast differentiation. Moreover, treatment with DHA attenuated the up-regulation of phosphorylation of phosphatidylinositol-3-kinase (PI3K) and protein kinase B (AKT) in UUO model and TGF-β1-induced primary human kidney fibroblasts.
We provide in vivo and in vitro evidence that DHA may relieve renal fibrosis through regulation of fibroblast proliferation and differentiation by mitigating the PI3K/AKT pathway. DHA may potentially be used as a therapeutic antifibrotic agent for the treatment of renal fibrosis.
肾纤维化是进行性肾病的最常见终末期,其特征为成纤维细胞增殖、成纤维细胞向肌成纤维细胞分化以及细胞外基质过度积聚。二氢青蒿素(DHA)具有抗肿瘤、抗菌和抗纤维化作用。本研究旨在确定 DHA 是否对单侧输尿管梗阻(UUO)诱导的小鼠肾纤维化具有有益作用,并探讨其潜在的可能机制。
8 周龄雄性 C57BL/6 小鼠在 UUO 手术后连续 14 天经口给予 DHA。然后,评估肾脏间质胶原沉积、胶原 I 和 III、纤维连接蛋白、α-平滑肌肌动蛋白(α-SMA)、增殖细胞核抗原(PCNA)和 S100 钙结合蛋白 A4(S100A4)的表达。用 DHA 处理转化生长因子β1(TGF-β1)诱导的原代人肾成纤维细胞,以进一步研究其作用机制。
体内,DHA 减轻了 UUO 诱导的形态和病理变化以及肾脏纤维化程度。此外,DHA 减轻了 UUO 诱导的肾组织中成纤维细胞增殖和分化。体外,DHA 显著减弱了 TGF-β1 诱导的原代人肾成纤维细胞增殖和纤维母细胞向肌成纤维细胞分化。此外,DHA 处理减弱了 UUO 模型和 TGF-β1 诱导的原代人肾成纤维细胞中磷酸肌醇-3-激酶(PI3K)和蛋白激酶 B(AKT)的磷酸化上调。
我们提供了体内和体外证据,表明 DHA 可能通过减轻 PI3K/AKT 通路来缓解肾纤维化,从而调节成纤维细胞增殖和分化。DHA 可能有望成为治疗肾纤维化的治疗性抗纤维化药物。